$65.9 million in funding from the mrff is available for 2016/17, with ALL programs now announced. detail of the ANNOUNCEMENTS  is provided below, with more information still to follow

MRFF Disbursements for 2016/17

  • $8 million is to be allocated across the four existing NHMRC Advanced Health Research Translation Centres (something Research Australia has advocated for over a year). Of this amount, Monash Partners AHRTC is receiving $2 million for research and initiatives to improve care in blood and lung cancer, cardiovascular disease diabetes dementia, and improve influenza vaccination rates. Sydney Health Partners AHRTC has been allocated $2.2 million for three programs, to address lower back pain, improve recruitment for clinical trials, and address gaps in the health system.  Detail of the other AHRTCs’ research programs has yet to be announced.
  • $2 million to support new and existing Advanced Health Research and Translation Centres (AHRTCs) and the two soon-to-be-announced Centres for Innovation in Regional Health (CIRHs) to work together on national system-level initiatives. Of this amount, $225,000 has been allocated to the recently announced Dimantina Partners AHRTC, and $225,000 to the newly announced The SPHERE (Sydney Partnership for Health, Education, Research and Enterprise) AHRTC. Details of how the rest of the funding is to be allocated is expected as the new CIRHs are announced.
  • $10 million in funding will be provided to The Australian Prevention Partnership Centre (TAPCC) to generate effective low-cost solutions to address chronic disease and childhood obesity.
  • $5 million for new targeted clinical trial activity for adolescents and young adults with cancer, to be administered by CanTeen.
  • $13 million over four years to increase clinical trials and registries’ capacity. This includes funding for networks of investigators and service providers that work together, to identify and evaluate new approaches that will optimise healthcare effectiveness.
  • $5 million over four years to the Australian Clinical Trials Alliance (ACTA) as the national alliance partner to build the capacity of clinical trials networks.
  • $8 million to boost the scale of three existing NHMRC Fellowship schemes- Career Development Fellowships, (early to mid-career researchers in clinical, population health, biomedical and bioinformatics fields); Translating Research into Practice Fellowships (health professionals translating evidence into healthcare and public health improvements) and Practitioner Fellowships (implementing evidence-based practice among clinical, public health and health service professionals). Fellowship awards will be announced from early 2017-18.
  • $2 million to the Coalition for Epidemic Preparedness Innovations (CEPI), a new international initiative to address critical research and development gaps for pandemic preparedness and global health security.
  • $5.9 million for antimicrobial resistance to address knowledge gaps in relation to the development and spread of resistance; and the development of new products, including diagnostic technologies and therapies, policies and approaches to prevent, detect and respond to resistance.
  • $5 million to establish the Biotech Horizons program, to provide early stage pre-clinical support for biotechnologies. An administrator for the program is yet to be appointed.
  • $2 million to Cure4MND for clinical trials for adults with MND. This  amount was provided as matching funding to public donations to Cure4MND’s ‘Big Freeze 3’ fundraising campaign.